膀胱癌中TERT启动子的全面突变分析及晨尿中突变的检测 - Suppr

Suppr

超能文献

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

作者信息

Hurst Carolyn D, Platt Fiona M, Knowles Margaret A

机构信息

Section of Experimental Oncology, Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK.

出版信息

Eur Urol. 2014 Feb;65(2):367-9. doi: 10.1016/j.eururo.2013.08.057. Epub 2013 Sep 3.

DOI:10.1016/j.eururo.2013.08.057

PMID:24035680

Abstract

摘要

相似文献

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.膀胱癌中TERT启动子的全面突变分析及晨尿中突变的检测

Eur Urol. 2014 Feb;65(2):367-9. doi: 10.1016/j.eururo.2013.08.057. Epub 2013 Sep 3.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.膀胱癌中端粒酶逆转录酶启动子突变：跨越多个阶段的高频率、尿液中的检测以及与结局无关。

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

TERT mutations in urine could predict bladder cancer recurrence.尿液中的端粒酶逆转录酶（TERT）突变可预测膀胱癌复发。

Lancet Oncol. 2017 Aug;18(8):e443. doi: 10.1016/S1470-2045(17)30538-7. Epub 2017 Jul 14.

Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.端粒酶逆转录酶基因启动子突变有助于辨别泌尿生殖系统肿瘤的起源：一项基因组和分子研究。

Eur Urol. 2014 Feb;65(2):274-7. doi: 10.1016/j.eururo.2013.10.038. Epub 2013 Nov 5.

Telomerase in bladder cancer: back to a better future?膀胱癌中的端粒酶：会迎来更美好的未来吗？

Eur Urol. 2014 Feb;65(2):370-1. doi: 10.1016/j.eururo.2013.10.019. Epub 2013 Oct 28.

The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.端粒酶逆转录酶（TERT）启动子的C228T突变频繁发生于膀胱癌干细胞中，并促进膀胱癌的肿瘤发生。

Oncotarget. 2015 Aug 14;6(23):19542-51. doi: 10.18632/oncotarget.4295.

TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.端粒酶逆转录酶（TERT）启动子突变和TERT信使核糖核酸（mRNA）是中国汉族膀胱尿路上皮癌患者的尿液生物标志物，但成纤维细胞生长因子受体3（FGFR3）突变不是。

Oncologist. 2015 Mar;20(3):263-9. doi: 10.1634/theoncologist.2014-0391. Epub 2015 Feb 5.

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.癌症。膀胱癌中 TERT 启动子突变与端粒酶激活。

Science. 2015 Feb 27;347(6225):1006-10. doi: 10.1126/science.1260200. Epub 2015 Feb 5.

Telomerase and other novel approaches to bladder cancer detection.端粒酶及其他膀胱癌检测的新方法。

Clin Lab Sci. 2008 Summer;21(3):185-90; quiz 191-2, following 192.

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.膀胱癌中 CpG 岛甲基化的全基因组分析鉴定 TBX2、TBX3、GATA2 和 ZIC4 为 pTa 特异性预后标志物。

Eur Urol. 2012 Jun;61(6):1245-56. doi: 10.1016/j.eururo.2012.01.011. Epub 2012 Jan 18.

引用本文的文献

The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by repressing extracellular matrix deposition and mechanotransduction signaling.ETS转录因子GABPA通过抑制细胞外基质沉积和机械转导信号来抑制膀胱癌的侵袭性。

Cell Death Dis. 2025 Aug 14;16(1):618. doi: 10.1038/s41419-025-07935-z.

The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible.端粒酶逆转录酶（TERT）启动子突变型癌症的永生机制具有自我强化性且是可逆的。

Mol Cell. 2025 Jun 19;85(12):2337-2354.e9. doi: 10.1016/j.molcel.2025.05.026. Epub 2025 Jun 12.

The Application of Microfluidic Chips in Primary Urological Cancer: Recent Advances and Future Perspectives.微流控芯片在原发性泌尿系统癌症中的应用：最新进展与未来展望

Smart Med. 2025 May 19;4(2):e70010. doi: 10.1002/smmd.70010. eCollection 2025 Jun.

Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.新兴生物活性技术与材料在膀胱癌诊断中对尿游离DNA的分析

Front Bioeng Biotechnol. 2024 Sep 4;12:1458362. doi: 10.3389/fbioe.2024.1458362. eCollection 2024.

Small cell neuroendocrine carcinoma and poorly differentiated rhabdomyosarcomas of the urinary bladder in adults-A comparative analysis in favor of a common histogenesis.成人膀胱小细胞神经内分泌癌和低分化横纹肌肉瘤——支持共同组织发生的比较分析。

Virchows Arch. 2024 Oct;485(4):615-623. doi: 10.1007/s00428-024-03835-3. Epub 2024 Jun 4.

Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors.年轻膀胱肿瘤患者的端粒酶逆转录酶启动子突变

Curr Issues Mol Biol. 2024 Mar 23;46(4):2845-2855. doi: 10.3390/cimb46040178.

Noncoding RNA Res. 2023 Oct 7;9(1):141-152. doi: 10.1016/j.ncrna.2023.10.003. eCollection 2024 Mar.

Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.膀胱癌的精准医学：当前挑战与未来方向。

J Pers Med. 2023 Apr 28;13(5):756. doi: 10.3390/jpm13050756.

Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer.解析端粒酶逆转录酶在头颈癌中的功能

Biomedicines. 2023 Feb 24;11(3):691. doi: 10.3390/biomedicines11030691.

promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance.膀胱癌中端粒酶激活的启动子突变和甲基化：新的机制见解和临床意义。

Front Immunol. 2023 Jan 12;13:1071390. doi: 10.3389/fimmu.2022.1071390. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验